ALAN DOUGLAS STRICKLAND, MD
Medical Practice at Waterlily St, Richwood, TX
License number
Texas E2885
Category
Medical Practice
Type
Pediatrics
Address
Address
101 Waterlily St, Richwood, TX 77566
Phone
(979) 265-5435
Professional information
Polymeric Compositions And Their Method Of Use In Combination With Active Agents
US Patent:
2011009, Apr 21, 2011
Filed:
Aug 29, 2008
Appl. No.:
12/675698
Inventors:
Alan Strickland - Lake Jackson TX, US
George Grass - Tahoe City CA, US
George Grass - Tahoe City CA, US
International Classification:
A61K 31/78, A61K 9/48, A61K 9/52, A61P 9/00, A61P 13/12
US Classification:
424457, 424 7831, 424463, 424451
Abstract:
A combination of active agents is disclosed which are particularly useful for treating fluid overload conditions. Methods for using the combination of active agent are also disclosed. The combination can include a highly absorbent polyelectrolyte polymer along with an agent that increases the amount of fluid in the intestine.
Determining Biodegradability Of Aspartic Acid Derivatives, Degradable Chelants, Uses And Compositions
US Patent:
5854060, Dec 29, 1998
Filed:
Sep 18, 1997
Appl. No.:
8/932972
Inventors:
Alan D. Strickland - Lake Jackson TX
Assignee:
The Dow Chemical Company - Midland MI
International Classification:
C07C 0000, B09B 300
US Classification:
435262
Abstract:
Chelants represented by Formula 1b: ##STR1## are determined to be biodegradable when Distance A is from about 3. 8. times. 10. sup. -10 to about 4. 6. times. 10. sup. -10 m, Distance B is from about 5. 1. times. 10. sup. -10 to about 5. 9. times. 10. sup. -10 m, and Distance C is from about 4. 3 to about 6. 7. times. 10. sup. -10 m). Compounds meeting these criteria are referred to as compounds of Formula 2. In addition to methods of analysis and computer systems therefor, the invention includes a method of chelating a metal ion to form a chelate and biodegrading the chelate comprising step (a) contacting the metal ion with at least one compound of Formula 2 to form a chelate and (b) contacting the resultant chelate or chelant with microbes of the type specified in ASTM 2667-89, ISO 5815 or effective enzymes thereof under conditions and for a time sufficient for biodegradation wherein either (i) the chelate formed in step (a) is formed in a process of removing deposits, scale, or rust; cleaning or washing; controlling metal initiated or catalyzed oxidation or deterioration including spoilage, discoloration, or rancidification; textile treatment; paper making; stabilization of polymers or phosphates; or petroleum drilling, production or recovery; or (ii) the chelate formed in step (a) is before step (b) used as a redox catalyst, in a process of photographic bleaching, bleach-fixing or developing; in electroless deposition or plating; in removing acid or oxide gases including H. sub. 2 S, NO. sub. X, SO. sub. X, CO and CO. sub. 2 ; or in providing agricultural nutrients.
Water-Soluble Polymers For The Reduction Of Dietary Phosphate Or Oxalate Absorption
US Patent:
2004017, Sep 2, 2004
Filed:
Mar 2, 2004
Appl. No.:
10/791061
Inventors:
Jaime Simon - Angleton TX, US
Tipton Masterson - Lake Jackson TX, US
Alan Strickland - Lake Jackson TX, US
Martha Hilton - Webster TX, US
Tipton Masterson - Lake Jackson TX, US
Alan Strickland - Lake Jackson TX, US
Martha Hilton - Webster TX, US
International Classification:
A61K031/765
US Classification:
424/078380
Abstract:
The present invention is directed to a water-soluble polyether glycol polymer having: a structural backbone of carbon atoms and oxygen atoms where there are at least two consecutive carbon atoms present between each oxygen atom; a moiety on the backbone of the polymer or a functionalized derivative on the polymer, that is cationic at physiological pH and permits complexation with phosphate or oxalate; and an average molecular weight from about 5,000 to about 750,000 Daltons. These polymers are formulated for oral dosage to reduce the phosphonate or oxalate levels in an animal. The process of preparing these polymers and the method of reducing gastrointestinal absorption of phosphate and oxalate are included.
Methods Of Achieving Transplantation Tolerance Through Radioablation Of Hemolymphopoietic Cell Populations
US Patent:
2003022, Dec 11, 2003
Filed:
Dec 10, 2002
Appl. No.:
10/316790
Inventors:
Luca Inverardi - Miami Beach FL, US
Camillo Ricordi - Miami FL, US
Giovanni Paganelli - Milano, IT
Aldo Serafini - Key Biscayne FL, US
Jaime Simon - Angleton TX, US
Alan Strickland - Lake Jackson TX, US
Camillo Ricordi - Miami FL, US
Giovanni Paganelli - Milano, IT
Aldo Serafini - Key Biscayne FL, US
Jaime Simon - Angleton TX, US
Alan Strickland - Lake Jackson TX, US
International Classification:
A61K051/00
US Classification:
424/001490
Abstract:
A method for achieving hemolymphopoietic chimerism is disclosed. The method involves the steps of administering to a recipient a bone seeking radiopharmaceutical; transplanting bone marrow-derived cells into the recipient; and transiently suppressing lymphocyte response so as to induce hemolymphopoietic chimerism. The method is useful for decreasing rejection of transplanted organs, tissues or cells and for treating autoimmune diseases. The present invention has the advantage of inducing hemolymphopoietic chimerism without the need for external radiation or harsh cytotoxic drugs. The present invention has the additional advantage of significantly prolonging tolerance to an organ, cell, or tissue transplant.
Radionuclide Therapy For Urinary Bladder Cancer
US Patent:
2009025, Oct 8, 2009
Filed:
Mar 23, 2007
Appl. No.:
12/225464
Inventors:
R. Keith Frank - Lake Jackson TX, US
Daniel J. Macey - Birmingham AL, US
Jaime Simon - Angleton TX, US
Alan D. Strickland - Lake Jackson TX, US
Daniel J. Macey - Birmingham AL, US
Jaime Simon - Angleton TX, US
Alan D. Strickland - Lake Jackson TX, US
International Classification:
A61K 51/04, A61P 39/04, A61P 35/00
US Classification:
424 165
Abstract:
The compounds used in this method for the treatment of bladder cancer comprise a radioisotope particle emitter, such as alpha- or beta-emitters or low energy gamma-emitters, associated with a chelating agent (for metallic radioisotopes) or other compound (by covalent bond for iodine or other non-metals) selected such that these permit delivery of the radionuclide by an I.V. injection that is then cleared into the bladder by the kidneys. Furthermore, it is expected that these radioisotopes are formulated with customary pharmaceutically-acceptable salts, adjuvants, binders, desiccants, diluents, and excipients.
Polyamino Monoesuccinates For Use In Photographic Processes
US Patent:
5585226, Dec 17, 1996
Filed:
Aug 30, 1995
Appl. No.:
8/521551
Inventors:
Alan D. Strickland - Lake Jackson TX
David A. Wilson - Richwood TX
Eric R. Brown - Webster NY
David A. Wilson - Richwood TX
Eric R. Brown - Webster NY
Assignee:
Eastman Kodak Company - Rochester NY
International Classification:
G03C 700, G03C 518, G03C 526, G03C 544
US Classification:
430393
Abstract:
Polyamino monosuccinic acid chelants are disclosed which have been found to be applicable in photographic processes. The polyamino monosuccinic acids can be used in a method of bleaching or bleach-fixing a silver halide photographic material comprising contacting the photographic material with a bleaching solution containing a metal complex of a polyamino monosuccinic acid as a bleaching agent.
Polymeric Compositions With Enhanced Saline Holding Capacity And Their Method Of Preparation And Use
US Patent:
2011010, May 5, 2011
Filed:
Aug 29, 2008
Appl. No.:
12/675689
Inventors:
Alan Strickland - Lake Jackson TX, US
George Grass - Tahoe City CA, US
George Grass - Tahoe City CA, US
Assignee:
SORBENT THERAPEUTICS, INC. - Vernon Hills IL
International Classification:
A61K 9/00, A61K 31/78, B01J 39/20
US Classification:
424400, 424 781, 521 38
Abstract:
Cross-linked polyelectrolyte polymers that absorb 60-fold or more, including greater than 60-fold, greater than 70-fold, greater than 80-fold, greater than 90-fold, greater than 100-fold, or greater than 110-fold or more, of their mass in a saline solution are disclosed. Methods for preparing such polymers with enhanced saline holding capacity and methods for treating diseases, disorders or conditions involving fluid overload and/or ion imbalances by administering the polymers are disclosed.
In Vivo Use Of Water Absorbent Polymers
US Patent:
8263112, Sep 11, 2012
Filed:
May 6, 2004
Appl. No.:
10/840112
Inventors:
Jaime Simon - Angleton TX, US
Alan D. Strickland - Lake Jackson TX, US
Alan D. Strickland - Lake Jackson TX, US
Assignee:
Sorbent Therapeutics, Inc. - Sunnyvale CA
International Classification:
A61K 9/16
US Classification:
424439, 424451, 424464, 424489
Abstract:
The subject invention is a method and material for removing fluid from the intestinal tract of a host and may be useful in treating animals or human patients suffering from fluid overload states. In one embodiment, the subject method involves ingesting an enterically coated non-systemic, non-toxic, non-digestible, water absorbing polymer which absorbs fluid while passing through the intestinal tract. The polymer is excreted in the feces wherein the polymer and absorbed fluid is removed from the body. Preferred polymers include super absorbent acrylic acid polymers, preferably provided in bead form. The polymers may include functional groups for selectively removing blood borne waste products, e. g. urea, from the G. I. tract.
In Vivo Use Of Water Absorbent Polymers
US Patent:
6908609, Jun 21, 2005
Filed:
Nov 6, 2001
Appl. No.:
10/036989
Inventors:
Jaime Simon - Angelton TX, US
Alan D. Strickland - Lake Jackson TX, US
Alan D. Strickland - Lake Jackson TX, US
Assignee:
Dow Global Technologies Inc. - Midland MI
International Classification:
A61K031/765, A61K009/52
US Classification:
424 783
Abstract:
The subject invention is a method and material for removing fluid from the intestinal tract of a host and may be useful in treating animals or human patients suffering from fluid overload states. In one embodiment, the subject method involves ingesting an enterically coated non-systemic, non-toxic, non-digestible, water absorbing polymer which absorbs fluid while passing through the intestinal tract. The polymer is excreted in the feces wherein the polymer and absorbed fluid is removed from the body. Preferred polymers include super absorbent acrylic acid polymers, preferably provided in bead form. The polymers may include functional groups for selectively removing blood borne waste products, e. g. urea, from the G. I. tract.
Radioiodinated Sulfonated Phenols And Process Therefore
US Patent:
6861044, Mar 1, 2005
Filed:
Dec 18, 2001
Appl. No.:
10/022885
Inventors:
Jaime Simon - Angleton TX, US
R. Keith Frank - Lake Jackson TX, US
Alan D. Strickland - Lake Jackson TX, US
R. Keith Frank - Lake Jackson TX, US
Alan D. Strickland - Lake Jackson TX, US
Assignee:
The Dow Chemical Company - Midland MI
International Classification:
A61K051/00
US Classification:
424 185
Abstract:
The present invention concerns the use of a radioiodinated phenolic compound of the formula
wherein: m and n are independently 0, 1, 2 or 3, X is a group that is negatively or positively charged at physiological pH, R, R, Rand Rare independently hydrogen, C-Calkyl, or a carboxyl group, and I* is I, I or I, and its pharmaceutically-acceptable salts. The compound is formulated and used in vivo in an animal in brachytherapy in an implantable catheter. In addition, due to the rapid renal clearance of these compounds, they may be used to study renal function. A process to prepare these compounds is also disclosed.